Current status of eye disorders caused by docetaxel administration every 3 weeks: A case-control study in Japanese patients

Noguchi, Yusuke ✉; Kawashima, Yugo; Maruyama, Megumi; Kawara, Hiroko; Tokuyama, Yoko; Uchiyama, Kiyoshi; Shimizu, Yoshihiro

English Scientific Article (Journal Article)
Published: JOURNAL OF ONCOLOGY PHARMACY PRACTICE 1078-1552 1477-092X Paper: UNSP 1078155219868761 , 11 p. 2019
  • SJR Scopus - Medicine (miscellaneous): Q2
    Purpose: Docetaxel is known to cause eye disorders. In this study, current status of eye disorders caused by docetaxel administration every 3 weeks in Japanese patients was examined. Methods:This case-control study targeted patients who were newly administered docetaxel at the Kyoto Okamoto Memorial Hospital between 1 July 2015 and 30 June 2018. Eye disorder occurrence was defined as an event in which the pharmacist confirmed the symptoms in a patient interview and the ophthalmologist diagnosed the disorder. Results: Of the 89 subjects, 7 (7.9%) had eye disorders. The symptoms were watering eyes (7.9%), a stye and eye discharge (2.2% each), corneal and conjunctival disorder, visual acuity reduction, and blepharedema (1.1% each). Four patients who presented with watering eyes, eye discharge, or corneal and conjunctival disorder showed improvement with the use of eye drops such as artificial tears. Two patients who presented with a stye showed improvement with the use of oral cefcapene. One patient with mild symptoms showed spontaneous improvement. However, one patient had irreversible visual acuity reduction. The multivariate logistic regression analysis revealed that a cumulative docetaxel dose of >= 300 mg/m(2) (odds ratio: 15.50, 95% confidence interval: 1.37-175.00, p = 0.027) and concomitant cyclophosphamide use (odds ratio: 13.20, 95% confidence interval: 1.13-153.00, p = 0.039) were significant risk factors associated with eye disorders. Conclusion: In conclusion, it was determined that docetaxel-related eye disorders might be influenced by the cumulative dose of docetaxel and concomitant cyclophosphamide use. In addition, relatively mild symptoms improved with medication.
    Citation styles: IEEEACMAPAChicagoHarvardCSLCopyPrint
    2021-06-24 02:30